1. home
  2. Publications
No Study Code Journal Title Link
139 KCSG HN15-16 J Clin Oncol . 2023 Sep 12:JCO2202786. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
138 KCSG UN14-13 Eur J Cancer . 2023 Nov:193:113312. doi: 10.1016/j.ejca.2023.113312. A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)
137 KCSG BR18-16 Eur J Cancer . 2023 Dec:195:113386. doi: 10.1016/j.ejca.2023.113386. Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
136 KCSG LU19-04 J Clin Oncol . 2023 Oct 20 00:1-11 Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)
135 KCSG BR12-09 N Engl J Med 2021;385:2336-47. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
134 KCSG HN15-16 Cancer Res Treat . 2023 Jul 20. doi: 10.4143/crt.2023.433. A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): In-Depth Analysis of Nintendanib Arm from the KCSG HN15-16 TRIUMPH Trial
133 KCSG GU18-18 ESMO Open. 2023 Jun 27;8(4):101588. doi: 10.1016/j.esmoop.2023.101588 Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
132 KCSG LY20-06 Korean J Intern Med. 2023 Jun 26. Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06).
131 KCSG BR21-18 Oncologist . 2023 Jun 5;oyad156. doi: 10.1093/oncolo/oyad156. A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast Cancer
130 KCSG RC20-09 Cancer Med. 2023 Jun 1. Online ahead of print. Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06
129 KCSG ST13-10 Cancer Res Treat. 2023 May 25. A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).
128 KCSG ST18-20 Oncologist . 2023 Apr 10;oyad059. doi: 10.1093/oncolo/oyad059. Online ahead of print. AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)
127 KCSG UN18-05 Journal of Cancer Research and Therapeutics. April 04, 2023 Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial)
126 KCSG HN13-01 Cancers (Basel). 2023 Jan 12;15(2):471. Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)
125 KCSG LU17-21 J Thorac Oncol. 2023 Feb;18(2):223-231. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)
124 KCSG BR18-14 Breast. 2022 Oct;65:172-178. Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)
123 KCSG LU21-11 Clin Lung Cancer. 2022 Dec;23(8):e536-e539. A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)
122 KCSG BR07-03 Cancer Res Treat. 2022 Nov 8. doi: 10.4143/crt.2022.1360. Online ahead of print. A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
121 KCSG PC21-20 Cancer Res Treat. 2022 Dec 27. Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
120 KCSG CO17-02 Clin Oncol (R Coll Radiol). 2023 Feb;35(2):e143-e152. Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02
119 KCSG BR19-15/ ST19-16 Ther Adv Med Oncol 2022;14:1-13 Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group
118 KCSG HB19-14 Lancet Gastroenterol Hepatol . 2023 Jan;8(1):56-65. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)
117 KCSG BR07-02 Breast Cancer Res Treat. 2015 Jul;152(1):77-85. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
116 KCSG PC17-01 Support Care Cancer. 2022 Sep;30(9):7431-7438. Discussing POLST facilitated hospice care enrollment in patients with terminal cancer.
115 KCSG LU19-22 Transl Lung Cancer Res 2022;11(7):1369-1379 Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
114 KCSG BR18-23 JAMA Oncol. 2022 Sep 1;8(9):1271-1277. Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
113 KCSG CO09-07 J Clin Oncol. 2022 Nov 20;40(33):3868-3877. Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
112 KCSG HN17-11 Clin Cancer Res. 2022 Oct 3;28(19):4240-4247. A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11)
111 KCSG BR13-11 ESMO Open. 2021 Oct; 6(5): 100236. Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
110 KCSG BR16-09 Cancer Res Treat. 2023 Jan;55(1):123-135. Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
109 KCSG LU20-11 Cancer . 2022 Feb 15;128(4):778-787. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)
108 KCSG HN13-01 Korean J Intern Med . 2022 Jan;37(1):190-200. Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
107 NA J Cancer. 2022 Jan 1;13(3):869-876. Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer
106 KCSG ST19-16 Gastric Cancer. 2022 May;25(3):609-618. Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide,real-world study in Korea (KCSG-ST19-16)
105 KCSG ST19-16 Ther Adv Med Oncol. 2021 Sep 18;13:17588359211042812. Ramucirumab plus paclitaxel as secondline treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
104 KCSG LU19-05 J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
103 NA Cancer Res Treat. 2022 Jan;54(1):1-9 Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
102 NA Liver Int. 2022 Mar;42(3):674-681. Efficacy and safety atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
101 KCSG LU17-13 J Thorac Oncol. 2018 Sep;13(9):1373-1382. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
100 KCSG HN14-06 Cancer Medicine. 2021 Oct;10(20):7012-7020 A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
99 KCSG LU13-05 BMC Cancer. 2021 Jul 12;21(1):802. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitornaive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
98 KCSG HN16-08 Clin Cancer Res. 2021 Oct 1;27(19):5272-5279. Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma
97 KCSG HN13-01 Cancer Res Treat. 2022 Jan;54(1):109-117. Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: the Concept of Chemo-Selection (KCSG HN13-01)
96 KCSG BR10-13 Cytokine. 2021 Jun;142:155487. Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)
95 NA ESMO Open. 2021 Apr;6(2):100049. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
94 KCSG PC13-09 Cancers (Basel). 2021 Jan 18;13(2):331. Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
93 KCSG HN18-12 Cancer Res Treat. 2021 Jul;53(3):671-677. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
92 KCSG LU16-07 Thorac Cancer. 2020 Dec; 11(12): 3482-3489. Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
91 KCSG BR15-10 Cancer Res Treat. 2021 Jul;53(3):695-702. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
90 KCSG HN18-12 J Cancer Res Clin Oncol. 2020 Dec;146(12):3359-3369 Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer
study group HN 18-12
89 KCSG HN12-12 Br J Cancer. 2020 Dec;123(12):1720-1729. Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
88 KCSG HN14-18 Cancer. 2020 Oct 15;126(20):4521-4531 Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma
87 KCSG BR15-10 Cancers (Basel) . 2020 Nov 5;12(11):3265. Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine
in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
86 KCSG UN17-16 Transl Cancer Res. 2020 May;9(5):3222-3230. Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)
85 KCSG HN13-01 BMC Cancer. 2020 Aug 27;20(1):813 Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01)
84 KCSG UN17-16 Mol Clin Oncol . 2017 Jul;7(1):27-31. Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
83 KCSG BR15-10 Lancet Oncol. 2019 Dec;20(12):1750-1759 Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
82 KCSG PC13-09 Oncologist. 2020 Mar;25(3):e502-e511. Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy
81 KCSG LU15-09 J Clin Oncol. 2020 Feb 10;38(5):488-495 Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations:
A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
80 KCSG GU12-03 Cancer Res Treat. 2018 Apr;50(2):488-494 Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma:A Single-Arm, Open-Label, Multicenter, Phase II Study
79 KCSG CO17-07 Cancer Res Treat. 2020 Oct;52(4):1135-1144. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
78 KCSG PC14-17 Support Care Cancer. 2020 Nov;28(11):5177-5183 Interference with daily functioning by breakthrough pain in patients with cancer
77 N/A Ther Adv Med Oncol. 2019 Aug 23;11:1758835919871126 Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.
76 KCSG GU10-16 Eur J Cancer. 2020 Mar;127:183-190 Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16)
75 KCSG BR11-16 Br J Cancer. 2019 Dec;121(12):985-990. Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
74 KCSG PC17-01 Cancer Res Treat. 2019 Oct;51(4):1632-1638 Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer
73 KCSG PC13-09 J Geriatr Oncol. 2019 Sep;10(5):749-756 Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors
72 KCSG BR13-11 Breast Cancer Res Treat. 2019 Nov;178(2):367-377 Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
71 KCSG GU17-03 Cancer Med. 2019 Sep;8(12):5431-5437 Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03
70 KCSG ST13-10 Contemp Clin Trials Commun. 2017 Aug 18;8:55-61 Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial
69 KCSG ST06-01 J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28 Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study(START)
68 KCSG GU11-03 Cancer Res Treat. 2019 Oct;51(4):1578-1588 Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
67 KCSG ST10-01 Oncologist. 2019 Jan;24(1):18-e24. A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01)
66 N/A Gastric Cancer. 2018 Sep;21(5):819-830. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)
65 KCSG HN15-16 Cancer Res Treat. 2019 Jan; 51(1): 300-312. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
64 KCSG BR10-04 Eur J Cancer. 2018 Nov;103:127-136. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
63 KCSG LU12-13 Cancer Res Treat. 2019 Apr;51(2):718-726. A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
62 KCSG PC13-02 Support Care Cancer. 2017 Dec;25(12):3759-3767. Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients
61 KCSG CO14-03 Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):889-899 A Randomized Phase II Trial of Consolidation Chemotherapy after Preoperative Chemoradiation versus Chemoradiation alone for Locally Advanced Rectal Cancer: KCSG CO 14-03
60 KCSG PC13-09 Br J Cancer.2018 May;118(9):1169-1175. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study.
59 KCSG LU12-07 Br J Cancer. 2018 Mar 6;118(5):648-653. Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
58 KCSG BR11-01 Cancer Res Treat. 2019 Jan;51(1):43-52. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
57 KCSG CO12-04 Korean J Intern Med. 2019 Jan;34(1):165-177. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean
Cancer Study Group CO12-04 study.
56 KCSG GU11-05 Cancer Res Treat. 2018 Oct;50(4):1252-1259. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
55 KCSG ST14-11 Gastric Cancer. 2018 Sep;21(5):802-810. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11
54 KCSG BR13-11 Eur J Cancer. 2017 Nov;86:385-393. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
53 KCSG LY16-01 Cancer Res Treat . 2018 Apr;50(2):590-598. Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01
52 KCSG LU13-08 J Clin Oncol. 2017 Aug 10;35(23):2613-2618 Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
51 KCSG GU14-08 Cancer Res Treat. 2016 Oct;48(4):1286-1292. Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08
50 KCSG LU05-04 J Clin Oncol. 2015 Aug 20;33(24):2660-6. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
49 KCSG 0806 Lung Cancer. 2016 Mar;93:1-8. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
48 KCSG PC10-09 Support Care Cancer. 2016 Apr;24(4):1709-17 A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
47 KCSG HN14-01 Cancer. 2017 Jun 1;123(11):1958-1964. Clinical Trial of Nintedanib in Patients with Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck:A Multicenter Phase 2 Study (Korean Cancer Study Group HN14-01)
46 KCSG HN12-02 Clin Cancer Res. 2015 Feb 1;21(3):544-52. Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
45 KCSG LU12-01 Oncotarget. 2017 Feb 28;8(9):15943-15951. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
44 KCSG HN12-08 Eur J Cancer. 2015 Aug;51(12):1588-95. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
43 KCSG HN13-06 Cancer Res Treat. 2017 Apr;49(2):416-422. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
42 KCSG HN11-08 Clin Cancer Res. 2015 Feb 1;21(3):544-52. Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
41 KCSG PC10-21 Oncologist. 2015 Dec;20(12):1440-7. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21
40 KCSG HN10-02 Radiother Oncol. 2016 Feb;118(2):244-50. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)
39 KCSG HN10-03 Ann Oncol. 2013 Dec;24(12):3089-94 A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
38 KCSG GY10-10 Gynecol Oncol. 2015 Feb;136(2):212-7 Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10
37 KCSG GU10-17 Br J Cancer. 2015 Jan 20;112(2):260-5 Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).
36 KCSG GU10-15 Br J Cancer. 2014 May 13;110(10):2472-8 Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
35 KCSG BR09-05 Ann Oncol. 2013 Jun;24(6):1485-90 Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).
34 KCSG LU08-01 Cancer. 2012 Dec 15;118(24):6234-42 Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
33 KCSG HN07-01 Eur J Cancer. 2012 Nov;48(17):3198-204 A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
32 KCSG BR07-02 J Clin Oncol. 2013 May 10;31(14):1732-9 Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
31 KCSG BR07-01 Breast Cancer Res Treat. 2012 Apr;132(2):589-600 Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
30 KCSG HB07-01 Invest New Drugs . 2012 Jun;30(3):1164-74. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research
29 KCSG CO06-01 Am J Clin Oncol . 2013 Dec;36(6):565-71. Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01.
28 KCSG CO06-08 Am J Clin Oncol. 2014 Feb;37(1):19-23 A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
27 KCSG ST06-13 Br J Cancer. 2009 Jan 27;100(2):298-304. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
26 KCSG ST06-02 Cancer Chemother Pharmacol. 2012 Nov;70(5):665-72 A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
25 KCSG LU06-04 Lung Cancer. 2009 Dec;66(3):338-43 Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.
24 KCSG ST06-14 Invest New Drugs. 2011 Apr;29(2):366-73 A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
23 KCSG ST05-05 Int J Clin Oncol. 2008 Jun;13(3):201-5 Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study).
22 KCSG BR06-01 Breast Cancer Res Treat. 2011 Jan;125(1):99-106. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
21 KCSG HB06-06 Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7 Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
20 NA Cancer Res Treat. 2008 Jun;40(2):87-92 Discrepant views of Korean medical oncologists and cancer patients on complementary and alternative medicine.
19 KCSG CO05-01 Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63 Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
18 KCSG LU05-03 Clin Cancer Res. 2010 Feb 15;16(4):1307-14 Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
17 KCSG ST05-01 Cancer Chemother Pharmacol. 2009 May;63(6):1083-90 A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
16 KCSG ST05-02 Asia Pac J Clin Oncol. 2009;5(1):46?54 Phase II study of S-1 and irinotecan combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05-02
15 KCSG LU05-01 J Thorac Oncol. 2009;4(9):1136-43 Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
14 KCSG LU05-02 Clin Cancer Res. 2008;14(12):3860-6 Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?
13 KCSG LY04-03 Oncologist. 2014 Nov;19(11):1129-30 A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group.
12 KCSG ST04-01 Jpn J Clin Oncol. 2007 Jul;37(7):501-8 Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.
11 IRB04-01 Asia Pac J Clin Oncol. 2014 Mar;10(1):38-52 Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics
10 KCSG HB03-01 Cancer Chemother Pharmacol. 2008 Oct;62(5):763-8 A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
9 KCSG ST03-03 (KCSG 03-06-25) Cancer Chemother Pharmacol. 2008 Jul;62(2):263-70 Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study.
8 KCSG LU02-01 (KCSG 02-09-17) J Clin Oncol. 2007;25:5233-9 Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.
7 KCSG 02-11-08 Cancer Chemother Pharmacol. 2008 Jan;61(1):47-52 Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
6 KCSG ST02-01 (KCSG 02-10-31) Cancer Res Treat. 2009;41(1):12-8 Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
5 KCSG CO01-01 (KCSG 01-11-17) Acta Oncol. 2005;44(3):230-5 Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
4 KCSG BR01-01 (KCSG 01-10-05) Oncol Rep. 2005 Aug;14(2):481-7 Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
3 N/A Ann Oncol. 2008 Aug;19(8):1477-84 Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group.
2 N/A Lung Cancer. 2006 Apr;52(1):75-81 Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.
1 N/A Cancer Res Treat. 2014;46(2):141-147 Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee.